Related news Ginkgo Bioworks Holdings (DNA) stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Tuesday. Â How To Use Stock Charts To Stay Profitable And Protected This unique rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database. Over 100 years… Cytokinetics Stock Scores RS Rating Jump To 83 ANALYSIS: The Market Threat From A Federal Shutdown Get instant access to exclusive stock lists, expe ...

Summary of Cytokinetics Conference Call Company Overview - **Company**: Cytokinetics - **Focus**: Development of muscle-directed medicines, particularly for cardiovascular and neuromuscular diseases [2][3] Key Points Pipeline and Product Development - **Aficamten**: A cardiac myosin inhibitor pending FDA review, targeting obstructive hypertrophic cardiomyopathy (OHCM) [3][4] - **Sequoia Study**: Phase 3 pivotal study with promising results, NDA submission with a PDUFA date of December 26, 2023 [4][6] - **Maple Study**: Phase 3 study showing improvements in peak VO2 compared to standard care [6][7] - **Acacia Study**: Focused on non-obstructive HCM, results expected in the first half of 2026 [7][8] - **Other Myosin Modulators**: - **Omecamtiv Mecarbil**: For heart failure with reduced ejection fraction (HFrEF) - **Eulocamten**: For heart failure with preserved ejection fraction (HFpEF) [5] Financial Position - **Cash Position**: Approximately $1 billion in cash and equivalents as of June, with access to an additional $425 million from previous deals [8][9] - **Refinancing**: Completed a $650 million refinancing to strengthen financial position [9] Market Strategy - **Target Market**: Specialty cardiology with high unmet needs, focusing on a concentrated customer segment [5][8] - **Commercialization Plans**: Aiming to build a specialty cardiology franchise over the next three to five years [8] Regulatory Expectations - **FDA Interactions**: Positive discussions regarding Aficamten's risk mitigation profile and potential labeling [10][11] - **Differentiation**: Aficamten expected to have a differentiated profile in terms of dosing and monitoring compared to existing therapies [11][19] Competitive Landscape - **Mavacamten**: First-in-class cardiac myosin inhibitor by Bristol Myers Squibb, currently capturing about 15% of diagnosed and treatment-eligible patients with OHCM [21][22] - **Market Growth**: Anticipation that Aficamten's approval could expand the cardiac myosin inhibitor market significantly [21][22] Clinical Data Insights - **Acacia Study Design**: Built on insights from previous studies, aiming for a positive outcome in non-obstructive populations [25][26] - **Patient Outcomes**: Previous studies showed significant improvements in functional class and NT-proBNP levels, indicating potential for positive results in Acacia [26][27] Conclusion - Cytokinetics is positioned to make significant advancements in the treatment of cardiac conditions with its innovative drug candidates, particularly Aficamten, while maintaining a strong financial foundation and strategic market approach [8][9][22]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi ...

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, alleging that the company made materially false and misleading statements regarding the New Drug Application (NDA) for aficamten, which could impact investors who acquired the company's securities during the specified class period [1][8]. Allegations - The lawsuit claims that Cytokinetics misrepresented the timeline for the NDA submission and approval process for aficamten, stating that FDA approval was expected in the second half of 2025 with a PDUFA date of September 26, 2025 [8]. - The company allegedly failed to disclose significant risks, particularly the non-submission of a required Risk Evaluation and Mitigation Strategy (REMS), which could lead to delays in regulatory approval [8]. Key Dates - Investors must contact the law firm before November 17, 2025, to be considered for the lead plaintiff motion deadline [4]. Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP, established in 1888, has extensive experience in securities litigation and aims to protect the rights of investors who have suffered financial harm due to misrepresented statements [5].

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission-form/?id=169623&from=3 CLASS ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-su ...

Core Insights - Aficamten shows significant improvements in exercise capacity and recovery compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM) and demonstrates long-term efficacy and tolerability in non-obstructive hypertrophic cardiomyopathy (nHCM) patients [1][2][6] Group 1: MAPLE-HCM Study Findings - Aficamten demonstrated a statistically significant improvement in peak oxygen uptake (pVO2) with a treatment difference of +2.3 mL/kg/min (p<0.001) compared to metoprolol [3] - Additional analyses revealed improvements in submaximal exercise performance, including anaerobic threshold (+76 mL, p<0.001) and aerobic efficiency (+0.8 mL/min/watt, p=0.004) [4][5] - Aficamten also improved post-exercise recovery metrics, with a faster VO2 recovery rate compared to metoprolol [3] Group 2: FOREST-HCM Study Findings - In the FOREST-HCM study, 79% of patients with nHCM improved by at least one NYHA Functional Class after 96 weeks of treatment, with 74% becoming asymptomatic [7] - Aficamten led to a mean increase of 11.2 points in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) [7] - Cardiac biomarkers such as NT-proBNP and high-sensitivity cardiac troponin I showed significant declines by Week 12 and remained low through Week 96 [7] Group 3: Aficamten Overview - Aficamten is a selective cardiac myosin inhibitor designed to reduce myocardial hypercontractility associated with hypertrophic cardiomyopathy (HCM) [9] - The drug is currently under evaluation in multiple clinical trials, including ACACIA-HCM for nHCM and CEDAR-HCM for pediatric patients with oHCM [11] - Aficamten has received Breakthrough Therapy Designation from the FDA for symptomatic HCM and is undergoing regulatory review in the U.S., Europe, and China [13]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging securities fraud and unlawful business practices related to the company's New Drug Application for aficamten [1]. Summary by Relevant Sections Class Action Details - Investors are encouraged to contact Pomerantz LLP to join the class action, with a deadline to appoint a Lead Plaintiff by November 17, 2025 [1]. - The lawsuit centers on whether Cytokinetics and its officers engaged in fraudulent activities concerning their securities [1]. FDA Interaction and Stock Impact - On March 10, 2025, Cytokinetics announced that the FDA would not hold an advisory committee meeting for aficamten's NDA [1]. - The FDA extended the action date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the need for a Risk Evaluation and Mitigation Strategy (REMS) that was not included in the original NDA [1]. - Following this announcement, Cytokinetics' stock price dropped by $5.57, or 12.98%, closing at $37.35 on May 2, 2025 [1]. - On May 6, 2025, CEO Robert I. Blum revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, leading to a further stock price decline of $2.70, or 7.36%, closing at $33.97 [1].

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly making false and misleading statements regarding the New Drug Application (NDA) for aficamten, which may have caused investor losses during the specified Class Period from December 27, 2023, to May 6, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics misrepresented the expected timeline for FDA approval of aficamten, indicating it would occur in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [5]. - Investors who purchased Cytokinetics common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, which has a strong track record in securities class actions, is representing the investors and encourages them to select qualified counsel with proven success [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 17, 2025, to represent the interests of the class members in the litigation [1][3].

Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and prospects, which led to investor losses [1]. Group 1: Cytokinetics, Incorporated (NASDAQ: CYTK) - The class period for Cytokinetics is from December 27, 2023, to May 6, 2025, with a lead plaintiff deadline of November 17, 2025 [2]. - Allegations include the failure to disclose the omission of a Risk Evaluation and Mitigation Strategy (REMS) from the initial New Drug Application (NDA), which resulted in a three-month delay in FDA approval processes [2]. - Defendants' positive statements about the company's business were deemed materially misleading due to these omissions [2]. Group 2: Quanex Building Products Corporation (NYSE: NX) - The class period for Quanex is from December 12, 2024, to September 5, 2025, with a lead plaintiff deadline of November 18, 2025 [4]. - The complaint alleges that the company underinvested in tooling and equipment maintenance, leading to degraded conditions that could incur significant costs and delay expected benefits from integration efforts [4]. - Positive statements made by the defendants regarding the company's operations were found to lack a reasonable basis due to these undisclosed issues [4]. Group 3: Jasper Therapeutics, Inc. (NASDAQ: JSPR) - The class period for Jasper is from November 30, 2023, to July 3, 2025, with a lead plaintiff deadline of November 18, 2025 [6]. - Allegations include the lack of necessary controls to ensure third-party manufacturers complied with current Good Manufacturing Practices (cGMP), which could negatively impact clinical trial results and the company's product prospects [6]. - Defendants' positive statements about the company's business and financial prospects were considered materially misleading due to these failures [6]. Group 4: KBR, Inc. (NYSE: KBR) - The class period for KBR is from May 6, 2025, to June 19, 2025, with a lead plaintiff deadline of November 18, 2025 [8]. - The complaint alleges that the company misled investors about the partnership with TRANSCOM, despite knowing of material concerns regarding HomeSafe's ability to fulfill contract obligations [8]. - Positive statements made by the defendants regarding the company's operations were found to lack a reasonable basis due to these undisclosed concerns [8].